Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

14.03
+0.01000.07%
Post-market: 14.030.00000.00%19:30 EDT
Volume:115.98K
Turnover:1.63M
Market Cap:478.34M
PE:-24.66
High:14.22
Open:14.14
Low:13.87
Close:14.02
52wk High:19.60
52wk Low:8.61
Shares:34.09M
Float Shares:23.28M
Volume Ratio:0.73
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5690
EPS(LYR):-0.6560
ROE:-103.27%
ROA:-7.47%
PB:40.25
PE(LYR):-21.39

Loading ...

3 Stocks Estimated To Be Undervalued By Up To 37.3% Offering Potential Opportunities

Simply Wall St.
·
Yesterday

NeuroPace Forecasts 2026 Revenue USD 99.5 Million-101.5 Million

Reuters
·
Aug 12

NeuroPace, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

NeuroPace Rugi Bersih GAAP Q2 FY26 Menyempit 38,1% Jadi USD 6,2 Juta; Revenue Naik 17% Jadi USD 22,8 Juta

Reuters
·
Aug 12

NeuroPace, Inc. Q2 EPS Usd -0.18

Reuters
·
Aug 12

Neuropace, Inc. Q2 EPS Usd -0.18

THOMSON REUTERS
·
Aug 12

Press Release: NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Dow Jones
·
Aug 12

NeuroPace, Inc. Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial

TIPRANKS
·
Jul 29

NeuroPace Price Target Maintained with a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

NeuroPace faces FDA setback on epilepsy label expansion

TIPRANKS
·
Jul 29

NeuroPace Says FDA Deems Epilepsy Label Expansion Filing not Approvable in Current Form

Reuters
·
Jul 29

Neuropace - Receives FDA Notice Pma Supplement for Ige not Approvable in Current Form

THOMSON REUTERS
·
Jul 29

Neuropace - to Submit Submission Issue Request and Amend Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Receives FDA Guidance on Pma Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

THOMSON REUTERS
·
Jul 29

Neuropace - FDA Requests Additional Clinical Evidence from Nautilus Trial for Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Inc : Mizuho Initiates Coverage with Outperform Rating; Target Price $22

THOMSON REUTERS
·
Jul 23

NeuroPace Shareholders Approve Directors and Auditor at Meeting

TIPRANKS
·
Jun 09

NeuroPace shareholders elect directors at annual meeting

Reuters
·
Jun 09